Aspirin Could Help Tackle Colon Cancer in Individuals Having a Specific Gene

People carrying high levels of a specific type of gene have a chance of reducing the risk of colon cancer by half with the intake of aspirin as per study released on Wednesday.

Researchers previously were aware that non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin could reduce colorectal cancer risks, but they did not understand why some saw a benefit and others did not, according to the study in Science Translational Medicine.

Key Steps Linking Dietary Fats and Colon Cancer Tumor Growth Found by Scientists
A new genetic evidence was shown by scientists that could strengthen the link between the role of dietary fats with colon cancer progression.

Scientists studied tissues from people who developed colon cancer while on an aspirin regimen then set out to understand why people with a particular gene appeared to get a protective benefit from aspirin and others did not.

They examined tissues of 270 colon cancer patients from 127,865 participants followed for over three decades.

They found that patients who lacked a genetic profile which yields high levels of the enzyme 15-PGDH got almost no protective benefit for colon cancer from aspirin.

Ant Colonies Help Evacuees in Disaster Zones
New research suggests that an escape route mapping system modeled on the behavior of ant colonies could give evacuees a better chance of reaching safe harbor.

"If you looked at the folks from the study who had high 15-PGDH levels and took aspirin, they cut their risk of colon cancer by half," said senior author Sanford Markowitz of Case Western Reserve School of Medicine.

Yet "if you looked at the folks from the study that were low for 15-PGDH, they did not benefit at all from taking aspirin. These findings represent a clean yes-no about who would benefit from aspirin," he explained.

Surveillance Colonoscopy Recommendations Found to be Consistent With Guidelines
The recommendation of endoscopists for timing of surveillance colonoscopy in average-risk patients is consistent with the guideline recommendations, a new study has found.

Identifying who can benefit from the colon cancer-reducing potential of aspirin is an important step because in some patients aspirin causes an increased risk of stomach ulcers and gastrointestinal bleeding, researchers said.

They are hoping to develop a test that would make it easy to identify who is and is not likely to get the positive effects of aspirin.

According to the American Cancer Society, colon cancer struck 137,000 Americans in 2014 and 50,000 will die of it. It is the second deadliest cancer after lung cancer.

But colon cancer deaths have been decreasing steadily over the past two decades as more and more people have sought testing, particularly colonoscopies.

Source-AFP